High plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are associated with hepatic dysfunction in patients with nonalcoholic fatty liver disease (NAFLD). However, it is unknown whether ADMA is involved in the pathogenesis of NAFLD. Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is an enzyme that degrades ADMA. In this study, we used Ddah1−/− mice to investigate the effects of the ADMA/DDAH1 pathway on high-fat diet (HFD)-induced hepatic steatosis.
Results:
After HFD feeding for 20 weeks, Ddah1−/− mice were more obese and had developed more severe hepatic steatosis and worse insulin resistance compared with wild-type (WT) mice. In the livers of HFD-fed mice, loss of DDAH1 resulted in higher levels of lipogenic genes, lower expression of β-oxidation genes, and greater induction of oxidative stress, endoplasmic reticulum stress, and inflammation than in the WT livers. Furthermore, ADMA treatment in HepG2 cells led to oxidative stress and steatosis, whereas overexpression of DDAH1 attenuated palmitic acid-induced steatosis, oxidative stress, and inflammation.
Innovation and Conclusion:
Our results provide the first direct evidence that the ADMA/DDAH1 pathway has a marked effect on hepatic lipogenesis and steatosis induced by HFD feeding. Our findings suggest that strategies to increase DDAH1 activity in hepatocytes may provide a novel approach to attenuate NAFLD development. Antioxid. Redox Signal. 26, 598–609.
Get full access to this article
View all access options for this article.
References
1.
AndreozziF, PrestaI, ManninoGC, ScarpelliD, Di SilvestreS, Di PietroN, SuccurroE, SciacquaA, PandolfiA, ConsoliA, HribalML, PerticoneF, and SestiG. A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity. PLoS One, 7: e36224, 2012.
2.
BakerRG, HaydenMS, and GhoshS. NF-kappaB, inflammation, and metabolic disease. Cell Metab, 13: 11–22, 2011.
3.
BestermannWHJr.The ADMA-metformin hypothesis: linking the cardiovascular consequences of the metabolic syndrome and type 2 diabetes. Cardiorenal Med, 1: 211–219, 2011.
4.
BogaS, AlkimH, KoksalAR, BayramM, OzguvenMB, ErgunM, NeijmannST, OzgonG, and AlkimC. Increased plasma levels of asymmetric dimethylarginine in nonalcoholic fatty liver disease: relation with insulin resistance, inflammation, and liver histology. J Investig Med, 63: 871–877, 2015.
5.
BugianesiE, GastaldelliA, VanniE, GambinoR, CassaderM, BaldiS, PontiV, PaganoG, FerranniniE, and RizzettoM. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia, 48: 634–642, 2005.
6.
CaiD, YuanM, FrantzDF, MelendezPA, HansenL, LeeJ, and ShoelsonSE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 11: 183–190, 2005.
7.
ChenP, XiaK, ZhaoZ, DengX, and YangT. Atorvastatin modulates the DDAH1/ADMA system in high-fat diet-induced insulin-resistant rats with endothelial dysfunction. Vasc Med, 17: 416–423, 2012.
8.
CohenJC, HortonJD, and HobbsHH. Human fatty liver disease: old questions and new insights. Science, 332: 1519–1523, 2011.
9.
ColakY, SenatesE, YesilA, YilmazY, OzturkO, DoganayL, CoskunpinarE, KahramanOT, MesciB, UlasogluC, and TuncerI. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine, 43: 100–107, 2013.
10.
DavidsM, RichirMC, VisserM, EllgerB, van den BergheG, van LeeuwenPA, and TeerlinkT. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Metabolism, 61: 482–490, 2012.
11.
De LucaB, MondaM, and SulloA. Changes in eating behavior and thermogenic activity following inhibition of nitric oxide formation. Am J Physiol, 268: R1533–R1538, 1995.
12.
DogruT, GencH, TapanS, AslanF, ErcinCN, OrsF, KaraM, SertogluE, KarsliogluY, BagciS, KurtI, and SonmezA. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf), 78: 712–717, 2013.
13.
DogruT, GencH, TapanS, ErcinCN, OrsF, AslanF, KaraM, SertogluE, BagciS, KurtI, and SonmezA. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. Diabetes Res Clin Pract, 96: 47–52, 2012.
14.
DruhanLJ, ForbesSP, PopeAJ, ChenCA, ZweierJL, and CardounelAJ. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry, 47: 7256–7263, 2008.
15.
DyckJR, KudoN, BarrAJ, DaviesSP, HardieDG, and LopaschukGD. Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. Eur J Biochem, 262: 184–190, 1999.
16.
El AssarM, AnguloJ, Santos-RuizM, Ruiz de AdanaJC, PindadoML, Sanchez-FerrerA, HernandezA, and Rodriguez-ManasL. Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute to endothelial dysfunction related to insulin resistance in rats and morbidly obese humans. J Physiol, 594: 3045–3060, 2016.
17.
FarrellGC and LarterCZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 43: S99–S112, 2006.
18.
FarrellGC, TeohNC, and McCuskeyRS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken), 291: 684–692, 2008.
19.
FerrignoA, Di PasquaLG, BerardoC, RichelmiP, and VairettiM. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. World J Gastroenterol, 21: 5131–5137, 2015.
20.
GregorMF and HotamisligilGS. Inflammatory mechanisms in obesity. Annu Rev Immunol, 29: 415–445, 2011.
21.
GuoW, DingJ, ZhangA, DaiW, LiuS, DiaoZ, WangL, HanX, and LiuW. The inhibitory effect of quercetin on asymmetric dimethylarginine-induced apoptosis is mediated by the endoplasmic reticulum stress pathway in glomerular endothelial cells. Int J Mol Sci, 15: 484–503, 2014.
22.
HaJ, DanielS, BroylesSS, and KimKH. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem, 269: 22162–22168, 1994.
23.
HanCY, KiSH, KimYW, NohK, Lee daY, KangB, RyuJH, JeonR, KimEH, HwangSJ, and KimSG. Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation. Antioxid Redox Signal, 14: 187–202, 2011.
24.
HardieDG and CarlingD. The AMP-activated protein kinase—fuel gauge of the mammalian cell?. Eur J Biochem, 246: 259–273, 1997.
25.
HasegawaK, WakinoS, KimotoM, MinakuchiH, FujimuraK, HosoyaK, KomatsuM, KanekoY, KandaT, TokuyamaH, HayashiK, and ItohH. The hydrolase DDAH2 enhances pancreatic insulin secretion by transcriptional regulation of secretagogin through a Sirt1-dependent mechanism in mice. FASEB J, 27: 2301–2315, 2013.
HuX, AtzlerD, XuX, ZhangP, GuoH, LuZ, FassettJ, SchwedhelmE, BogerRH, BacheRJ, and ChenY. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol, 31: 1540–1546, 2011.
28.
LengYP, QiuN, FangWJ, ZhangM, HeZM, and XiongY. Involvement of increased endogenous asymmetric dimethylarginine in the hepatic endoplasmic reticulum stress of type 2 diabetic rats. PLoS One, 9: e97125, 2014.
29.
Li VoltiG, SalomoneS, SorrentiV, MangiameliA, UrsoV, SiarkosI, GalvanoF, and SalamoneF. Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. Cardiovasc Diabetol, 10: 62, 2011.
30.
LluchP, TorondelB, MedinaP, SegarraG, Del OlmoJA, SerraMA, and RodrigoJM. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol, 41: 55–59, 2004.
31.
LuoY, YueW, QuanX, WangY, ZhaoB, and LuZ. Asymmetric dimethylarginine exacerbates Abeta-induced toxicity and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med, 79: 117–126, 2015.
32.
MaJ, ZhaoS, GaoG, ChangH, MaP, and JinB. Probucol protects against asymmetric dimethylarginine-induced apoptosis in the cultured human brain microvascular endothelial cells. J Mol Neurosci, 57: 546–553, 2015.
33.
MarchesiniG, BriziM, BianchiG, TomassettiS, BugianesiE, LenziM, McCulloughAJ, NataleS, ForlaniG, and MelchiondaN. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 50: 1844–1850, 2001.
34.
McCuskeyRS, ItoY, RobertsonGR, McCuskeyMK, PerryM, and FarrellGC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology, 40: 386–393, 2004.
35.
MeakinPJ, ChowdhryS, SharmaRS, AshfordFB, WalshSV, McCrimmonRJ, Dinkova-KostovaAT, DillonJF, HayesJD, and AshfordML. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol, 34: 3305–3320, 2014.
36.
MookerjeeRP, DaltonRN, DaviesNA, HodgesSJ, TurnerC, WilliamsR, and JalanR. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl, 13: 400–405, 2007.
37.
MookerjeeRP, MalakiM, DaviesNA, HodgesSJ, DaltonRN, TurnerC, SenS, WilliamsR, LeiperJ, VallanceP, and JalanR. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology, 45: 62–71, 2007.
38.
MookerjeeRP, MehtaG, BalasubramaniyanV, Mohamed FelZ, DaviesN, SharmaV, IwakiriY, and JalanR. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol, 62: 325–331, 2015.
39.
MuoioDM, SeefeldK, WittersLA, and ColemanRA. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J, 338 (Pt 3): 783–791, 1999.
40.
NajbauerJ, JohnsonBA, YoungAL, and AswadDW. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. J Biol Chem, 268: 10501–10509, 1993.
41.
NozakiY, FujitaK, WadaK, YonedaM, ShinoharaY, ImajoK, OgawaY, KessokuT, NakamutaM, SaitoS, MasakiN, NagashimaY, TerauchiY, and NakajimaA. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution. BMC Gastroenterol, 15: 177, 2015.
42.
OkadaT, YoshidaH, AkazawaR, NegishiM, and MoriK. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J, 366: 585–594, 2002.
43.
RaznyU, Kiec-WilkB, WatorL, PolusA, DyduchG, SolnicaB, MaleckiM, TomaszewskaR, CookeJP, and Dembinska-KiecA. Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance. Cardiovasc Diabetol, 10: 68, 2011.
44.
RensenSS, SlaatsY, NijhuisJ, JansA, BieghsV, DriessenA, MalleE, GreveJW, and BuurmanWA. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol, 175: 1473–1482, 2009.
45.
SamovskiD, SunJ, PietkaT, GrossRW, EckelRH, SuX, StahlPD, and AbumradNA. Regulation of AMPK activation by CD36 links fatty acid uptake to beta-oxidation. Diabetes, 64: 353–359, 2015.
46.
SantoroN, CaprioS, GianniniC, KimG, KursaweR, PierpontB, ShawMM, and FeldsteinAE. Oxidized fatty acids: a potential pathogenic link between fatty liver and type 2 diabetes in obese adolescents?. Antioxid Redox Signal, 20: 383–389, 2014.
47.
Sayki ArslanM, TurhanS, DincerI, MizrakD, CorapciogluD, and IdilmanR. A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with non-alcoholic fatty liver disease. Diabetol Metab Syndr, 6: 109, 2014.
48.
SchattenbergJM, SinghR, WangY, LefkowitchJH, RigoliRM, SchererPE, and CzajaMJ. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology, 43: 163–172, 2006.
49.
SheldonRD, PadillaJ, JenkinsNT, LaughlinMH, and RectorRS. Chronic NOS inhibition accelerates NAFLD progression in an obese rat model. Am J Physiol Gastrointest Liver Physiol, 308: G540–G549, 2015.
50.
SudaO, TsutsuiM, MorishitaT, TasakiH, UenoS, NakataS, TsujimotoT, ToyohiraY, HayashidaY, SasaguriY, UetaY, NakashimaY, and YanagiharaN. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol, 24: 1682–1688, 2004.
51.
TargherG, BertoliniL, PadovaniR, RodellaS, TessariR, ZenariL, DayC, and ArcaroG. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 30: 1212–1218, 2007.
52.
TargherG, DayCP, and BonoraE. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med, 363: 1341–1350, 2010.
53.
VallanceP, LeoneA, CalverA, CollierJ, and MoncadaS. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 339: 572–575, 1992.
54.
ZhangYL, GuoH, ZhangCS, LinSY, YinZ, PengY, LuoH, ShiY, LianG, ZhangC, LiM, YeZ, YeJ, HanJ, LiP, WuJW, and LinSC. AMP as a low-energy charge signal autonomously initiates assembly of AXIN-AMPK-LKB1 complex for AMPK activation. Cell Metab, 18: 546–555, 2013.
55.
ZhaoC, LiT, HanB, YueW, ShiL, WangH, GuoY, and LuZ. DDAH1 deficiency promotes intracellular oxidative stress and cell apoptosis via a miR-21-dependent pathway in mouse embryonic fibroblasts. Free Radic Biol Med, 92: 50–60, 2016.
56.
ZhengJ, WangK, JinP, DongC, YuanQ, LiY, and YangZ. The association of adipose-derived dimethylarginine dimethylaminohydrolase-2 with insulin sensitivity in experimental type 2 diabetes mellitus. Acta Biochim Biophys Sin (Shanghai), 45: 641–648, 2013.
57.
ZouMH, HouXY, ShiCM, KirkpatickS, LiuF, GoldmanMH, and CohenRA. Activation of 5′-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells. Role of peroxynitrite. J Biol Chem, 278: 34003–34010, 2003.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
